145 related articles for article (PubMed ID: 19229339)
1. Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.
Jeong M; Kwon YS; Park SH; Kim CY; Jeun SS; Song KW; Ko Y; Robbins PD; Billiar TR; Kim BM; Seol DW
PLoS One; 2009; 4(2):e4545. PubMed ID: 19229339
[TBL] [Abstract][Full Text] [Related]
2. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy.
Kim CY; Park SH; Jeong M; Kwon OS; Doh H; Kang SH; Robbins PD; Kim BM; Seol DW; Kim BG
Exp Mol Med; 2011 Oct; 43(10):580-6. PubMed ID: 21822049
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy in B-NHL cell line using adenovirus-mediated transfer of secretable trimeric TRAIL gene expression driven by CD20 promoter.
Yuan XF; Peng HW; Ding YH; Yan CH; Zhang YJ; Yang M; Xiong DS
Exp Hematol; 2013 Mar; 41(3):221-30. PubMed ID: 23142221
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
[TBL] [Abstract][Full Text] [Related]
6. TRAIL-secreting mesenchymal stem cells promote apoptosis in heat-shock-treated liver cancer cells and inhibit tumor growth in nude mice.
Deng Q; Zhang Z; Feng X; Li T; Liu N; Lai J; Shuai L; Xiong Q; Fu C; Zou H; Wang Y; Li X; Ma K; Bie P
Gene Ther; 2014 Mar; 21(3):317-27. PubMed ID: 24451114
[TBL] [Abstract][Full Text] [Related]
7. Human menstrual blood-derived mesenchymal stem cells as a cellular vehicle for malignant glioma gene therapy.
Wang XJ; Xiang BY; Ding YH; Chen L; Zou H; Mou XZ; Xiang C
Oncotarget; 2017 Aug; 8(35):58309-58321. PubMed ID: 28938558
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells.
Kim KU; Seo SY; Heo KY; Yoo YH; Kim HJ; Lee HS; Choi SS; Hwang TH; Lee HJ
J Korean Med Sci; 2005 Dec; 20(6):1046-52. PubMed ID: 16361820
[TBL] [Abstract][Full Text] [Related]
9. A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.
Oh E; Hong J; Kwon OJ; Yun CO
Sci Rep; 2018 Jan; 8(1):1420. PubMed ID: 29362367
[TBL] [Abstract][Full Text] [Related]
10. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886.
Kim SM; Woo JS; Jeong CH; Ryu CH; Lim JY; Jeun SS
Cancer Res; 2012 Sep; 72(18):4807-17. PubMed ID: 22962275
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer.
Zhang X; Cheung RM; Komaki R; Fang B; Chang JY
Clin Cancer Res; 2005 Sep; 11(18):6657-68. PubMed ID: 16166445
[TBL] [Abstract][Full Text] [Related]
12. Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells.
Jacob D; Schumacher G; Bahra M; Davis J; Zhu HB; Zhang LD; Teraishi F; Neuhaus P; Fang BL
World J Gastroenterol; 2005 May; 11(17):2552-6. PubMed ID: 15849810
[TBL] [Abstract][Full Text] [Related]
13. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
15. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
Marcantonio D; Panasci LC; Hollingshead MG; Alley MC; Camalier RF; Sausville EA; Dykes DJ; Carter CA; Malspeis L
Cancer Res; 1997 Sep; 57(18):3895-8. PubMed ID: 9307267
[TBL] [Abstract][Full Text] [Related]
16. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
Seol DW
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628
[TBL] [Abstract][Full Text] [Related]
17. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
[TBL] [Abstract][Full Text] [Related]
18. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Kurpad SN; Dolan ME; McLendon RE; Archer GE; Moschel RC; Pegg AE; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1997; 39(4):307-16. PubMed ID: 9025771
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29.
Xu XM; He C; Hu XT; Fang BL
World J Gastroenterol; 2003 May; 9(5):965-9. PubMed ID: 12717839
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma.
Naumann U; Waltereit R; Schulz JB; Weller M
J Neurooncol; 2003 Jan; 61(1):7-15. PubMed ID: 12587790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
